cross-sectional study asked a hard-hitting question: how often do oncology trialists commit the methodological sin of changing their primary endpoints after a study is already underway? Since such an occurrence is often brushed under the rug, they actually reviewed all protocol documents available from inception as well as analyzed tracked changes on ClincalTrials.gov. It turns out, a whopping one in five (n=145 of 755) published trials did change in primary endpoint from initial to final reporting. What’s more, less than a third (n=43) of these mentioned the change in the final manuscript. As suspected, trials with detected changes in primary endpoint had increased odds (OR 1.86) of achieving said primary endpoint. | Florez, JAMA Netw Open 2023
